LOW-LEVEL PRETRANSPLANT CMV DNAEMIA IS ALREADY A RISK FACTOR FOR POSTTRANSPLANT CMV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Prevymis (letermovir) - Merck (MSD)

https://ebmt2026.abstractserver.com/programme/#/details/presentations/1267

Catia Vieira Gomes1; Manuel Schibler1; Laurent Kaiser1; Yves Chalandon1; Stavroula Masouridi-Levrat1; Christian Van Delden1; Dionysios Neofytos1; Lena Royston1

Mar 14, 2026